Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
765.720.52%
QQQ
709.140.21%
BTC/USD
77220.380.2224%
DIA
530.300.48%
GLD
400.630.98%
TLT
81.860.01%

Fennec Pharmaceuticals Inc

FENCNASDAQ
Trade with Public
Trade with Public
$12.03
Last update: Sep 1, 4:00 PM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Fennec Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Fennec Pharmaceuticals (FENC).

Price Target Range — 10 Quarters

Analyst Consensus — 5 Analysts

5Buy
Consensus RatingBuy# Analysts5Avg. Consensus PT$16Upside to Avg. PT+36.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026B. Riley SecuritiesMadison El-SaadiPT RaiseBuy$16→$18
Aug 12, 2026WedbushDavid NierengartenPT RaiseOutperform$13→$16
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Reiterates Buy on Fennec Pharmaceuticals, Raises Price Target to $18

B. Riley Securities analyst Madison El-Saadi reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $16 to $18.
Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Fennec Pharmaceuticals, Raises Price Target to $16

Wedbush analyst David Nierengarten maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and raises the price target from $13 to $16.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Fennec Pharmaceuticals, Raises Price Target to $16

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Fennec Pharmaceuticals (NASDAQ:FENC) with a Buy and raises the price target from $13 to $16.
Benzinga Newsdesk

PRO
Wedbush Reiterates Outperform on Fennec Pharmaceuticals, Maintains $13 Price Target

Wedbush analyst David Nierengarten reiterates Fennec Pharmaceuticals (NASDAQ:FENC) with a Outperform and maintains $13 price target.
Benzinga Newsdesk

Fennec Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Fennec Pharmaceuticals (FENC) to release Q4 earnings on March 24. Analysts expect EPS of $0.04 and revenue of $14.73 million. Stock gained 1.8% on Monday.
Avi Kapoor

PRO
Piper Sandler Initiates Coverage On Fennec Pharmaceuticals with Overweight Rating, Announces Price Target of $18

Piper Sandler analyst David Amsellem initiates coverage on Fennec Pharmaceuticals (NASDAQ:FENC) with a Overweight rating and announces Price Target of $18.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved